April 22nd 2024
In separate, live virtual events, Kami J. Maddocks, MD, and Sairah Ahmed, MD, discussed the use of loncastuximab tesirine for a patient with later-line diffuse large B-cell lymphoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Khan Reviews Later-Line Therapy Options for DLBCL With Subgroup Considerations
July 10th 2022During a Targeted Oncology case-based roundtable event, Cyrus M. Khan, MD, discussed the data supporting the use of polatuzumab, bendamustine, and rituximab, tasfasitamab plus lenalidomide, and loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Polatuzumab Shows Improved Survival and Complete Responses in R/R DLBCL
July 6th 2022Ian W. Flinn, MD, PhD, discusses the study design and results of the phase 2 trial of the antibody-drug conjugate polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.
Watch
Considering Alternatives to CAR T-Cell Therapy for Primary Refractory DLBCL
June 20th 2022During a live virtual event, Jakub Svoboda, MD, discussed with participants the choice of therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who would not receive stem cell transplant or chimeric antigen receptor therapy.
Read More
Part 2: Selecting a Non-CAR T-Cell Treatment in Third-Line R/R DLBCL
June 6th 2022During a live virtual event, Jason Westin, MD, discussed with participants the choice of third-line treatment for relapsed/refractory diffuse large B-cell lymphoma for a patient who declines chimeric antigen receptor T-cell therapy.
Read More
Tafasitamab Plus Lenalidomide Bests Standard Treatments in Key High-Risk R/R DLBCL Subgroups
June 6th 2022According to Grzegorz S. Nowakowski, MD, results from a subgroup analysis of the observational RE-MIND study may aid in contextualizing therapy options for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Read More
Roundtable Discussion: Budde Focuses on the Factors Affecting Treatment Decisions in B-cell Lymphoma
June 4th 2022During a Targeted Oncology case-based event, Elizabeth Budde, MD, PhD, discussed with participants the case of a patient with relapsed/refractory diffuse large B-cell lymphoma who was not eligible for stem cell transplant and declined chimeric antigen receptor T-cell therapy.
Read More
Yazbeck Considers the Use of New Approaches in Relapsed/Refractory DLBCL
April 29th 2022During a Targeted Oncology case-based roundtable event, Victor Yazbeck, MD, MS, discussed the data from recent clinical trials of tafasitamab/lenalidomide, polatuzumab vedotin, and loncastuximab tesirine for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Gopal Addresses Differences Between Real-World and Clinical Trial Data for DLBCL
March 22nd 2022During a Targeted Oncology case-based roundtable event, Ajay K. Gopal, MD, discussed the options for second-line and subsequent treatment of a patient with relapsed/refractory diffuse large B-cell lymphoma who refuses CAR T-cell therapy.
Read More
Part 1: Tafasitamab/Lenalidomide Shows Durable Responses in R/R DLBCL
March 9th 2022During a live virtual event, Philippe Armand, MD, PhD, discussed the results of the outcomes of clinical trials of tafasitamab plus lenalidomide as well as loncastuximab tesirine in diffuse large B-cell lymphoma.
Read More
Subgroup Analysis Improves Understanding of Frontline DLBCL Options
February 25th 2022Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma, and while many trials have failed to change the standard of care and improve outcomes, new opportunities for targeted treatment are growing, according to Brian T. Hill, MD, PhD.
Read More
Lunning Discusses Second-Line Treatments in Diffuse Large B-Cell Lymphoma
January 31st 2022During a Targeted Oncology case-based roundtable event, Matthew A. Lunning, DO, discussed the results of the L-MIND study of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma.
Read More
VITALIZE to Validate the Efficacy/Safety of Maveropepimut-S Plus Pembrolizumab for R/R DLBCL
January 13th 2022A phase 2b study aims to confirm positive efficacy and safety results previously reported with the combination of maveropepimut-S and pembrolizumab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Read More